In the long and complex journey of cancer care, patients and caregivers often focus on major medical decisions—whether to undergo surgery, choose chemotherapy, or start immunotherapy. However, alongside these critical choices, many “small decisions” made daily can quietly shape the course of recovery and overall well-being.
In contemporary cancer care, circulating tumor cells (CTCs) are emerging not just as markers of disease activity, but as active contributors to personalized management strategies. For patients with metastatic colorectal cancer (mCRC), the enumeration and molecular analysis of CTCs offer insights into prognosis, therapy monitoring, and customized care planning.
Exploring the Auxiliary Role of CTC Detection in Observing Bone Metastasis in Cancer Exploring the Auxiliary Role of CTC Detection in Observing Bone Metastasis in
In cancer recovery and supportive care, nutrition is more than just replenishing nutrients — it plays a strategic role in the body’s healing process. Tailoring the type and dosage of nutrients based on an individual’s constitution and physiological response can significantly enhance quality of life, treatment tolerance, and immune function. Studies have shown that nutritional intervention may reduce systemic inflammation and support better therapeutic outcomes .
In the process of cancer care, more and more patients are seeking additional methods, alongside conventional medical treatments, to help boost energy levels and adjust their physical and mental state. Whether through diet, nutritional supplementation, or lifestyle changes, many people hope to find a method that aligns more closely with their individual needs throughout their care journey.
In recent years, the incidence of cancer among younger populations has been increasing at an alarming rate. More individuals in their 20s, 30s, and 40s are being diagnosed with various forms of cancer. Factors such as lifestyle changes, environmental pollution, chronic stress, and genetic predisposition are contributing to this trend. However, conventional cancer screening methods are primarily designed for older adults, leaving younger individuals without regular early detection opportunities. As a result, cancers in younger patients are often diagnosed at later stages, reducing the chances of successful intervention. RGCC personalized cancer testing offers a groundbreaking solution by detecting circulating tumor cells (CTCs) and cancer stem cells (CSCs) in the blood, allowing for early detection and providing personalized care strategies. This advanced technology is particularly valuable for younger populations, enabling proactive cancer prevention, early intervention, and tailored management plans.
In the process of cancer care, formulating a precise and personalized care plan has always been a major challenge. Traditional imaging and tumor marker tests are commonly used but often fail to comprehensively reflect the real-time dynamics and microscopic biological characteristics of tumors. With rapid advancements in liquid biopsy and genetic testing technologies, RGCC’s Onconomics Plus integrated analysis provides richer and more accurate data to support personalized care decisions, enabling healthcare teams to adjust care plans in a timely manner and ultimately improve patient prognosis and quality of life.
In the care process of cancer patients, there is often a gap period between initial treatments (such as surgery, chemotherapy, or radiotherapy) and regular follow-up visits. During this time, patients may not exhibit obvious symptoms, but residual or newly-formed tumor cells may persist, posing a risk of recurrence or metastasis. Traditional imaging techniques (such as CT or MRI) have limited sensitivity in detecting small lesions. Therefore, dynamic monitoring of micro-residual cancer cells during these gaps is crucial.
Hong Kong has one of the highest liver cancer incidence rates globally, largely due to chronic hepatitis B virus (HBV) infection, alcohol consumption, and fatty liver disease. However, early-stage liver cancer often presents no obvious symptoms, leading to late diagnoses when treatment options become more limited. This makes a highly sensitive and convenient early detection method crucial.
Hong Kong has one of the highest lung cancer incidence rates globally, even among non-smokers. Since early-stage lung cancer often presents no obvious symptoms, many patients are diagnosed at an advanced stage, missing the best opportunity for timely care. Therefore, finding a more sensitive and early screening method is crucial for improving survival rates.